Completed PHASE3 INTERVENTIONAL NCT00138983

Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.

Prevention of Glucocorticoid-Induced Osteoporosis in Patients With Rheumatic Diseases. The STOP-Study: a Randomized Placebo Controlled Trial With Alendronate Versus Alfacalcidol.

Sponsor: Dutch Health Care Insurance Board

Conditions Giant Cell Arteritis Polymyalgia Rheumatica Polymyositis Rheumatoid Arthritis Wegener's Granulomatosis

Interventions Alendronate versus alfacalcidol (1-alpha OH vitamin D)

Updated 6 times since 2017 Last updated: Nov 28, 2006 Started: May 31, 2000 Completion: Nov 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00138983, this PHASE3 trial focuses on Giant Cell Arteritis and Polymyalgia Rheumatica and remains completed. Sponsored by Dutch Health Care Insurance Board, it has been updated 6 times since 2000, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Sep 2020 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Sep 2020 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dutch Health Care Insurance Board
UMC Utrecht

Data source: UMC Utrecht

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Utrecht, Netherlands